◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...
Customize Items

Oruka Therapeutics, Inc.

CIK: 907654 SIC: 2834
-
Revenue
$-105.43M
Net Income
-
Gross Margin
-
Op. Margin
$-153.36M
Free Cash Flow
Financial Statements Annual (10-K)
Showing 5 of 15 annual reports available (2011 - 2025)
Breakdown TTM
(Dec 31, 2025)
FY 2025
(Dec 31, 2025)
FY 2024
(Dec 31, 2024)
FY 2023
(Dec 31, 2023)
FY 2022
(Dec 31, 2022)
FY 2021
(Dec 31, 2021)
Operating Expenses $122.05M $122.05M $88.12M $7.30M $10.60M $19.34M
Research & Development $100.64M $100.64M $75.06M $1.01M $4.75M $13.83M
Operating Income $-122.05M $-122.05M $-88.12M $-7.30M $-10.60M $-19.34M
Interest Expense - - $1.47M - - -
Interest Income $16.63M $16.63M $5.86M - - -
Other Income/Expense $-12.00K $-12.00K $4.00K - - -
Income Before Tax - $-105.43M $-83.72M - - $-19.32M
Net Income $-105.43M $-105.43M $-83.72M $-5.34M $-9.93M $-19.32M
Basic EPS nan nan -3.87 -0.37 -0.69 -1.39
Diluted EPS nan nan -3.87 -0.37 -0.69 -1.39
Basic Shares Outstanding - - 16.8M 14.4M 14.4M 13.9M
Diluted Shares Outstanding - - 16.8M 14.4M 14.4M 13.9M
Breakdown FY 2025
(Dec 31, 2025)
FY 2024
(Dec 31, 2024)
FY 2023
(Dec 31, 2023)
FY 2022
(Dec 31, 2022)
FY 2021
(Dec 31, 2021)
Cash & Cash Equivalents $46.94M $61.58M $37.43M $42.45M $53.36M
Short-term Investments $290.11M $314.07M - - -
Other Current Assets $6.81M $1.22M $161.00K $254.00K $1.06M
Total Current Assets $343.86M $376.87M $37.59M $42.70M $54.42M
Property Plant & Equipment $288.00K $162.00K $10.00K $25.00K $48.00K
Long-term Investments $142.54M $18.07M - - -
Other Non-current Assets $103.00K $43.00K $12.00K $18.00K $18.00K
Total Assets $488.62M $396.02M $37.86M $43.09M $54.92M
Accounts Payable - - $362.00K $334.00K $1.12M
Total Current Liabilities $15.37M $13.04M $637.00K $1.13M $3.50M
Total Liabilities $16.69M $13.80M $841.00K $1.41M $3.88M
Common Stock $49.00K $37.00K $14.00K $14.00K $14.00K
Retained Earnings $-189.16M $-83.72M $-188.74M $-183.40M $-173.48M
Total Stockholders Equity $471.93M $382.22M $37.02M $41.67M $51.04M
Total Liabilities & Equity $488.62M $396.02M $37.86M $43.09M $54.92M
Breakdown TTM
(Dec 31, 2025)
FY 2025
(Dec 31, 2025)
FY 2024
(Dec 31, 2024)
FY 2023
(Dec 31, 2023)
FY 2022
(Dec 31, 2022)
FY 2021
(Dec 31, 2021)
Net Income $-105.43M $-105.43M $-83.72M $-5.34M $-9.93M $-19.32M
Depreciation & Amortization - - - $15.00K $20.00K $16.00K
Stock-based Compensation $39.08M $24.24M $14.92M $686.00K $556.00K $497.00K
Change in Payables - - - $28.00K $-783.00K $-411.00K
Operating Cash Flow $-153.09M $-88.21M $-57.84M $-5.01M $-10.91M $-18.76M
Capital Expenditure $269.00K $209.00K $189.00K - $2.00K $43.00K
Purchases of Investments $717.54M $520.96M $329.94M - - -
Investing Cash Flow $-6.15M $-96.75M $-330.13M - $-2.00K $-43.00K
Stock Issued - $671.00K $54.00K - - $24.07M
Financing Cash Flow - $170.31M $449.54M - - $23.09M
Net Change in Cash - - - $-5.01M $-10.91M $4.29M
SEC Filing Format - Data shown as it appears in the Q3 2025 (10-Q) filing Period ended: Sep 30, 2025
Condensed Consolidated Statements of Operations
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Operating Expenses $34.10M - $87.62M -
Research & Development $28.99M - $73.00M -
Operating Income $-34.10M - $-87.62M -
Interest Expense - - - -
Interest Income $3.83M - $11.78M -
Other Income/Expense $3.83M - $11.77M -
Net Income $-30.28M $-22.24M $-75.85M -
Condensed Consolidated Balance Sheets
Description Sep 30, 2025 Dec 31, 2024
Cash & Cash Equivalents $91.25M $61.58M
Short-term Investments $257.90M $314.07M
Other Current Assets $6.01M $1.22M
Total Current Assets $355.16M $376.87M
Property Plant & Equipment $253.00K $162.00K
Long-term Investments $151.76M $18.07M
Other Non-current Assets $103.00K $43.00K
Total Assets $509.25M $396.02M
Total Current Liabilities $20.97M $13.04M
Total Liabilities $22.46M $13.80M
Common Stock $48.00K $37.00K
Retained Earnings $-159.57M $-83.72M
Total Stockholders Equity $486.79M $382.22M
Total Liabilities & Equity $509.25M $396.02M
Condensed Consolidated Statements of Cash Flows
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Net Income $-30.28M $-22.24M $-75.85M -
Stock-based Compensation - - $20.12M -
Operating Cash Flow - - $-65.62M -
Capital Expenditure - - $146.00K -
Purchases of Investments - - $419.97M -
Investing Cash Flow - - $-74.72M -
Stock Issued - - $109.00K -
Financing Cash Flow - - $170.02M -

All values are in USD (United States Dollars). Data is sourced from SEC EDGAR 10-K filings.

Annual data represents full fiscal year results. FY = Fiscal Year ending.

NEWS
Loading article...
NEWS
Loading news...
TRENDING
Loading...